Project Details
Description
Low-density lipoprotein cholesterol (LDL-C) is a causative factor in the development of atherosclerotic
cardiovascular disease (ASCVD), and lipid-lowering therapy can markedly reduce this risk. Yet, when to begin
lipid-lowering therapy has not been well understood. Despite the increasing rates of ASCVD in US young
adults aged 18-39 years over the past two decades, use of lipid-lowering therapy remained low, with
| Status | Finished |
|---|---|
| Effective start/end date | 4/5/23 → 1/31/24 |
Funding
- National Heart, Lung, and Blood Institute: US$787,387.00
ASJC Scopus Subject Areas
- Safety, Risk, Reliability and Quality
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.